Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

PSTV
PLUS THERAPEUTICS, Inc. Common Stock
stock NASDAQ

At Close
May 16, 2025 3:59:30 PM EDT
0.4158USD-17.923%(-0.0908)4,197,311
0.00Bid   0.00Ask   0.0000Spread
Pre-market
May 16, 2025 9:26:30 AM EDT
0.4600USD-9.199%(-0.0466)276,348
After-hours
May 16, 2025 4:58:30 PM EDT
0.4298USD+3.367%(+0.0140)30,717
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 18, 2022
06:00AM EST  A Peek Into The Markets: US Stock Futures Down Ahead Of Goldman Sachs Earnings   Benzinga
Jan 14, 2022
04:23PM EST  Plus Therapeutics Announces Offering Of Up To $5M   Benzinga
Jan 7, 2022
07:00AM EST  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will participate at two virtual conferences in January.   GlobeNewswire Inc
Jan 6, 2022
01:40PM EST  Plus Therapeutics shares were trading higher after the company announced that it has entered into an agreement with UT Health San Antonio for a worldwide exclusive license to develop and commercialize novel interventional therapeutics for cancer.   Benzinga
07:02AM EST  Plus Therapeutics Expands Investigational Oncology Drug Pipeline   Benzinga
07:02AM EST  Plus Therapeutics Says 'Initial IND Submission For Treatment Of Liver Cancer Planned In 2022'   Benzinga
07:02AM EST  Plus Therapeutics Expands Its Investigational Oncology Drug Pipeline   Benzinga
07:00AM EST  Plus Therapeutics Significantly Expands Investigational Oncology   GlobeNewswire Inc
Jan 4, 2022
08:11AM EST  The Daily Biotech Pulse: Liquidia Jumps On New CEO Appointment, Spectrum, Aravive Secure New Funding, Allena To Explore Strategic Alternatives   Benzinga
07:00AM EST  IsoTherapeutics Group LLC to develop and supply cGMP grade Rhenium-186 isotope for Plus Therapeutics Rhenium-186 NanoLiposome (186RNL) radiotherapeutic   GlobeNewswire Inc
Dec 2, 2021
07:30AM EST  Plus Therapeutics to Present at MedInvest Oncology Investor Conference   GlobeNewswire Inc
Nov 18, 2021
02:18PM EST  Plus Therapeutics' Targeted Radiotherapy Shows Encouraging Overall Survival In Brain Tumour Trial   Benzinga
08:05AM EST  Plus Therapeutics Highlights Presentation Of Data From ReSPECT-GBM Phase 1 Clinical Trial At 2021 Society For Neuro-Oncology Annual Meeting   Benzinga
08:00AM EST  Latest interim analysis shows Rhenium-186 NanoLiposome (186RNL) well-tolerated without dose-limiting toxicities   GlobeNewswire Inc
Nov 15, 2021
10:37AM EST  The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More   Benzinga
Nov 12, 2021
07:30AM EST  Plus Therapeutics Announces New Employment Inducement Grants   GlobeNewswire Inc
Nov 9, 2021
11:31AM EST  Plus Therapeutics Receives FDA Fast Track Designation For 186RNL Targeted Radiotherapeutic For Leptomeningeal Metastases   Benzinga
07:00AM EST  Plus Therapeutics Receives FDA Fast Track Designation for 186RNL   GlobeNewswire Inc
Nov 3, 2021
07:00AM EDT  Plus Therapeutics to Host Key Opinion Leader Roundtable on   GlobeNewswire Inc
Oct 27, 2021
02:00PM EDT  Plus Therapeutics Announces Presentation Of ReSPECT-GBM Trial Dosimetery Data At American Society For Radiation Oncology (ASTRO) 2021 Annual Meeting   Benzinga
02:00PM EDT  Data demonstrated Rhenium-186 NanoLiposome (186RNL) provides sustained, localized radiation treatment for over eight days to the tumor with minimal whole brain and body radiation exposure   GlobeNewswire Inc
Oct 21, 2021
04:15PM EDT  Plus Therapeutics Q3 EPS $(0.28) Misses $(0.21) Estimate   Benzinga
04:05PM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced financial results for the third quarter ended September 30, 2021, and provided an overview of recent business highlights.   GlobeNewswire Inc
12:11PM EDT  The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO   Benzinga
12:11PM EDT  Earnings Scheduled For October 21, 2021   Benzinga
Oct 19, 2021
07:32AM EDT  Plus Therapeutics Announces FDA Clearance Of Investigational New Drug Application For 186RNL For Treatment Of Leptomeningeal Metastases   Benzinga
07:30AM EDT  Patient accrual for the Phase 1 dose escalation clinical trial of 186RNL (ReSPECT-LM) is expected in the fourth quarter of 2021   GlobeNewswire Inc
Oct 18, 2021
07:34AM EDT  The Week Ahead In Biotech (Oct. 18-23): J&J, Biogen Kickstart Big Pharma Earnings, Regeneron-Sanofi, Roche Await FDA Decisions And IPOs   Benzinga
Oct 14, 2021
07:30AM EDT  Plus Therapeutics to Announce Third Quarter 2021 Financial Results   GlobeNewswire Inc
Sep 30, 2021
08:00AM EDT  Plus Therapeutics to Present ReSPECT-GBM   GlobeNewswire Inc
Sep 27, 2021
07:38AM EDT  Plus Therapeutics To Present At Benzinga Healthcare Small Cap Conference Sept. 30   Benzinga
07:30AM EDT  Plus Therapeutics to Present at the Benzinga Healthcare Small Cap   GlobeNewswire Inc
Sep 23, 2021
07:30AM EDT  Plus Therapeutics to Present Rhenium-186 NanoLiposome Data at the   GlobeNewswire Inc
Sep 17, 2021
07:36AM EDT  The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold   Benzinga
Sep 13, 2021
07:00AM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced the appointment of Norman LaFrance, M.D. to the position of Chief Medical Officer and Senior Vice President.   GlobeNewswire Inc
Sep 8, 2021
07:00AM EDT  Plus Therapeutics to Present at the H.C. Wainwright Global   GlobeNewswire Inc
Sep 2, 2021
02:56PM EDT  EXCLUSIVE: Plus Therapeutics President Marc Hedrick Comments On Manufacturing Deal With RadioMedix, Tells Benzinga Agreement 'helps us get one step further in bringing RNL to a registrational clinical trial and ultimately commercial supply'   Benzinga
08:20AM EDT  The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab   Benzinga
07:53AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Thursday, Sept. 2, 2021: GME, BAX, ETWO, FCUV, PSTV   Benzinga
07:02AM EDT  Plus Therapeutics Reports Commercial Manufacturing Supply Deal For Its Lead Investigational Drug, No Terms Disclosed   Benzinga
07:00AM EDT  RadioMedix, Inc. is a key manufacturer and supplier of cGMP radiotherapeutics for late-stage clinical trials and commercial production   GlobeNewswire Inc
Aug 21, 2021
09:24AM EDT  Data shows that the administration of Rhenium-186 NanoLiposome (186RNL) via convection enhanced delivery for recurrent glioblastoma is well tolerated at significantly higher doses of radiotherapy than with standard modalities   GlobeNewswire Inc
Aug 19, 2021
10:57AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
08:13AM EDT  Plus Therapeutics Shares Preclinical Data For Targeted Cancer Radiation Therapy: Highlights   Benzinga
07:37AM EDT  The Daily Biotech Pulse: Coherus Soars On Lung Cancer Data, Illumina Closes On Grail Buy Without Regulatory Clearance, Adagene Strikes Collaboration With Merck   Benzinga
07:07AM EDT  Plus Therapeutics Presents Data from Preclinical Study of Rhenium-186 Nanoliposome in Leptomeningeal Metastases and Plans for Further Evaluation with Upcoming Phase 1 Clinical Trial   Benzinga
07:00AM EDT  Positive data to support FDA IND application for the clinical evaluation of Rhenium-186 Nanoliposome (186RNL) targeted radiotherapy for patients with leptomeningeal metastases (LM)   GlobeNewswire Inc
Aug 15, 2021
12:16PM EDT  The Week Ahead In Biotech: Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow   Benzinga
11:06AM EDT  The Week Ahead In Biotech (Aug. 15-21): Fate Therapeutics Data Readout, RenovoRx IPO In Focus Amid Tapering Earnings News Flow   Benzinga
Aug 13, 2021
07:54AM EDT  Plus Therapeutics To Present Data From ReSPECT-GBM Trial At American Association Of Neurological Surgeons 2021 Annual Scientific Meeting   Benzinga
07:51AM EDT  Plus Therapeutics to Present Data from   GlobeNewswire Inc
Aug 11, 2021
10:15AM EDT  Plus Therapeutics To Present Data From 2 Studies Supporting Treatment Of Leptomeningeal Metastases With Rhenium-186 Nanoliposome   Benzinga
10:12AM EDT  Plus Therapeutics to Present Data from Two Studies Supporting the   GlobeNewswire Inc
Aug 5, 2021
07:30AM EDT  Plus Therapeutics to Present at Canaccord Genuity 41st Annual   GlobeNewswire Inc
Aug 4, 2021
07:52AM EDT  The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings   Benzinga
Aug 3, 2021
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
Jul 28, 2021
07:33AM EDT  The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal   Benzinga
Jul 27, 2021
11:13AM EDT  Plus Strengthens Commercial RNL Supply Chain with Ten Year Exclusivity Agreement   Benzinga
Jul 22, 2021
04:18PM EDT  Plus Therapeutics Q2 EPS $(0.25) Misses $(0.24) Estimate   Benzinga
11:34AM EDT  The Daily Biotech Pulse: FDA Nod For Merck-Eisai, Seres' Ulcerative Colitis Drug Flunks Midstage Study, Pfizer To Invest In Arvinas, Absci IPO   Benzinga
07:04AM EDT  Plus Therapeutics Highlights Treatment Of First Patient In Latest Dosing Cohort In ReSPECT-GBM Trial   Benzinga
07:00AM EDT  Plus Successfully Treats First Patient in Latest Dosing Cohort in   GlobeNewswire Inc
04:02AM EDT  Earnings Scheduled For July 22, 2021   Benzinga
Jun 16, 2021
08:30AM EDT  Plus Therapeutics Gets DSMB Approval To Start Eighth Cohort For Glioblastoma Trial   Benzinga
07:35AM EDT  Plus Therapeutics Announces DSMB Approval to Proceed into Eighth Cohort in ReSPECT Glioblastoma Trial   Benzinga
07:30AM EDT  Plus Therapeutics Announces DSMB Approval to Proceed into Eighth   GlobeNewswire Inc
Jun 10, 2021
07:30AM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), a clinical-stage pharmaceutical company, today announced it will present a poster at the 6th Biennial Pediatric Neuro-Oncology Research Conference hosted by the Society for Neuro-Oncology (SNO), being held virtually June 10-12, 2021.   GlobeNewswire Inc
Jun 9, 2021
04:15PM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), a clinical-stage pharmaceutical company, today announced that Marc H. Hedrick M.D., President and Chief Executive Officer of Plus Therapeutics, will participate in the BIO Digital Conference being held June 10-11 and 14-18, 2021.   GlobeNewswire Inc
May 4, 2021
07:40AM EDT  Plus Therapeutics Announces Key RNL Development And cGMP Drug Manufacturing Collaboration Agreements   Benzinga
07:30AM EDT  Plus Therapeutics Announces Key   GlobeNewswire Inc
Apr 23, 2021
12:07PM EDT  Plus Therapeutics shares were trading lower after the company reported Q1 earnings results.   Benzinga
Apr 22, 2021
04:13PM EDT  Plus Therapeutics Q1 EPS $(0.33) Beats $(0.34) Estimate   Benzinga
04:05PM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced financial results for the first quarter ended March 31, 2021, and provided an overview of recent business highlights.   GlobeNewswire Inc
12:21PM EDT  Earnings Scheduled For April 22, 2021   Benzinga
08:09AM EDT  The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs   Benzinga
04:01AM EDT  Earnings Scheduled For April 22, 2021   Benzinga
Apr 8, 2021
07:30AM EDT  Plus Therapeutics to Announce First Quarter 2021 Financial Results   GlobeNewswire Inc
Mar 23, 2021
07:34AM EDT  Plus Therapeutics Enters Into Master Services Agreement With Piramal Pharma Solutions; Financial Details Not Disclosed   Benzinga
07:30AM EDT  Plus Therapeutics Enters Into Master Services Agreement with   GlobeNewswire Inc
Mar 18, 2021
07:30AM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at the following upcoming virtual conferences.   GlobeNewswire Inc
Mar 5, 2021
11:51AM EST  Insider Buys Plus Therapeutics Shares   Benzinga
Mar 4, 2021
11:04AM EST  Insider Buys Plus Therapeutics Stock   Benzinga
Mar 3, 2021
07:30AM EST  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), a clinical-stage pharmaceutical company developing novel, targeted therapies for rare and difficult to treat cancers, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at the following upcoming virtual conferences.   GlobeNewswire Inc
Feb 22, 2021
04:18PM EST  Plus Therapeutics Reports FY20 EPS $(1.86) Up From $(8.27) YoY   Benzinga
04:05PM EST  Positive interim data through cohort five for the ReSPECT Phase 1 clinical trial in recurrent glioblastoma, announced November 2020   GlobeNewswire Inc
04:02AM EST  Earnings Scheduled For February 22, 2021   Benzinga
Feb 11, 2021
04:15PM EST  Plus Therapeutics to Announce Fourth Quarter and Full Year 2020   GlobeNewswire Inc
07:30AM EST  Plus Therapeutics to Participate in BIO CEO & Investor Digital   GlobeNewswire Inc
Feb 10, 2021
11:56AM EST  Plus Therapeutics Shares Spike to High; Halted on Circuit-Breaker   Benzinga
11:55AM EST  Plus Therapeutics Shares Spike to High; Halted on CB   Benzinga
Jan 25, 2021
10:18AM EST  Ladenburg Thalmann Initiates Coverage On Plus Therapeutics with Buy Rating, Announces Price Target of $8   Benzinga
09:49AM EST  5 Value Stocks In The Healthcare Sector   Benzinga
Jan 12, 2021
06:14AM EST  Plus Therapeutics On Jan. 8 Entered Into Agreement With Piramal Pharma Solutions; Piramal To Perform Some Services Related To Development, Manufacture, Supply Of Co's RNL-Liposome Intermediate Drug Product, Agreement Has A Term Of Five Years   Benzinga
Jan 11, 2021
10:12AM EST  5 Value Stocks To Watch In The Healthcare Sector   Benzinga
Jan 5, 2021
04:15PM EST  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), a clinical-stage company focused on making a positive impact on patients lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, will present at three upcoming virtual conferences.   GlobeNewswire Inc
Dec 15, 2020
07:30AM EST  Plus Therapeutics Completes Sixth Dosing Cohort in   GlobeNewswire Inc
Dec 14, 2020
11:22AM EST  Insider Buys Plus Therapeutics Stock   Benzinga
Dec 8, 2020
07:30AM EST  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), a clinical-stage company focused on making a positive impact on patients lives, today announced that Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, has been invited to present a Company overview during the 13th Annual LD Micro Main Event Conference on Monday, December 14th at 10:40 a.m. ET.   GlobeNewswire Inc
Dec 7, 2020
09:49AM EST  A Look Into Healthcare Sector Value Stocks   Benzinga
Dec 2, 2020
11:44AM EST  Insider Buys Plus Therapeutics Shares   Benzinga
Dec 1, 2020
07:40AM EST  Plus Therapeutics Expands ReSPECT Clinical Trial to MD Anderson Cancer Center   Benzinga
07:30AM EST  Plus Therapeutics Expands ReSPECT Clinical Trial   GlobeNewswire Inc
Nov 19, 2020
08:21AM EST  Plus Therapeutics Announces Positive New Interim Data From ReSPECT Phase 1 Clinical Trial   RTTNews
08:18AM EST  Plus Therapeutics To Present Interim Data From ReSPECT Phase 1 Clinical Trial In Recurrent Glioblastoma At Society For Neuro-Oncology Annual Meeting Nov. 19-21   Benzinga
08:17AM EST  The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway   Benzinga
08:00AM EST  Investigational drug RNLdeliversup to fifteentimes the absorbed dose of radiation compared to standard external beam radiationtherapy   GlobeNewswire Inc
Nov 16, 2020
08:00AM EST  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), a clinical-stage company focused on making a positive impact on patients lives, today announced that Company management has been invited to participate in two upcoming virtual investor conferences:   GlobeNewswire Inc
Nov 13, 2020
07:30AM EST  Company Management and Principal Investigator of ReSPECT to Discuss Interim Data   GlobeNewswire Inc
Nov 5, 2020
07:00AM EST  Plus Therapeutics Announces Formation of Scientific Advisory Board   GlobeNewswire Inc
Oct 29, 2020
05:36PM EDT  Plus Therapeutics Inc Files Prospectus Relates To Offer, Sale Of Up To 1.519M Shares Of Common Stock By Lincoln Park Capital Fund, Llc   Benzinga
07:47AM EDT  Plus Therapeutics Announces Initiation of Final Cohort of ReSPECT Glioblastoma Trial   Benzinga
07:00AM EDT  Plus Therapeutics Announces Initiation of Final Cohort of   GlobeNewswire Inc
Oct 22, 2020
04:16PM EDT  Plus Therapeutics Q3 EPS $(0.39) Beats $(0.65) Estimate   Benzinga
04:05PM EDT  ReceivedFDA Orphan Drug and Fast Track designations for novel glioblastoma radiotherapy   GlobeNewswire Inc
07:52AM EDT  The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat   Benzinga
04:38AM EDT  Earnings Scheduled For October 22, 2020   Benzinga
Oct 16, 2020
12:06PM EDT  Maxim Group Initiates Coverage On Plus Therapeutics with Buy Rating, Announces Price Target of $6   Benzinga
Oct 15, 2020
07:01AM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), today announced that it has been invited to participate in the Cancer Innovation Summit. The meeting, which is hosted by Health Tech Austin, is being held virtually on Thursday, October 22 from 12.00 to 3.00 p.m. EDT.   GlobeNewswire Inc
Oct 14, 2020
04:15PM EDT  Plus Therapeutics to Announce Third Quarter 2020 Financial Results   GlobeNewswire Inc
Oct 6, 2020
06:19AM EDT  Plus Therapeutics On September 30, Entered Into A Purchase Agreement And A Registration Rights Agreement With Lincoln Park Capital Fund   Benzinga
Oct 2, 2020
07:01AM EDT  Plus Therapeutics Announces The Appointment of 5 Leading Experts In The Fields Of Neurological Surgery And Neuro-Oncology To Its Clinical Advisory Board   Benzinga
07:00AM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), today announced the appointment of five leading experts in the fields of neurological surgery and neuro-oncology to its Clinical Advisory Board (CAB). The CAB will advise the Company as it advances its nanoscale radiotherapeutics to treat rare brain and neurological cancers.   GlobeNewswire Inc
Oct 1, 2020
07:09AM EDT  Plus Therapeutics Announces That It Will Present Its ReSPECT Glioblastoma Clinical Trial Data At The 2020 Society for Neuro-Oncology Annual Meeting   Benzinga
07:00AM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), today announced that its abstract regarding lead investigational drug, Rhenium NanoLiposomes (RNL), was accepted to the 2020 Society for Neuro-Oncology (SNO) Annual Meeting being held virtually on November 19-21, 2020.   GlobeNewswire Inc
Sep 28, 2020
10:01AM EDT  A Look Into Healthcare Sector Value Stocks   Benzinga
Sep 15, 2020
10:16AM EDT  Mid-Morning Market Update: Markets Open Higher; Cracker Barrel Beats Q4 Views   Benzinga
09:52AM EDT  Return On Capital Employed Overview: Plus Therapeutics   Benzinga
07:25AM EDT  Plus Therapeutics Receives Fast Track Designation For Rhenium NanoLiposomes From FDA For Recurrent Glioblastoma   RTTNews
07:02AM EDT  Plus Therapeutics Receives Fast Track Designation From FDA for Its Glioblastoma Treatment   Benzinga
07:00AM EDT  Plus Therapeutics Receives Fast Track Designation From FDA for Its   GlobeNewswire Inc
Sep 9, 2020
07:00PM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), today announced that it has been invited to present at the 22nd H. C. Wainwright Annual Global Investment Conference, which is being held virtually on September 14-16, 2020.   GlobeNewswire Inc
Sep 3, 2020
07:00AM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), today announced that it has been invited to present at the 9th Annual Gateway Conference, which is being held virtually on September 9-10, 2020.   GlobeNewswire Inc
Sep 1, 2020
11:41AM EDT  Why Plus Therapeutics Stock Is Trading Higher Today   Benzinga
11:10AM EDT  Plus Therapeutics shares are trading higher after the company announced the FDA has granted the company orphan drug designation for Rhenium NanoLiposomes for the treatment of patients with recurrent glioblastoma.   Benzinga
10:28AM EDT  A Look Into Plus Therapeutics's Price Over Earnings   Benzinga
10:13AM EDT  Return On Capital Employed Overview: Plus Therapeutics   Benzinga
07:33AM EDT  Plus Therapeutics Receives FDA Orphan Drug Designation For   RTTNews
07:20AM EDT  Plus Therapeutics Says FDA Granted Orphan Drug Designation For Rhenium NanoLiposomes   RTTNews
07:08AM EDT  Plus Therapeutics, Inc. Receives FDA Orphan Drug Designation For Novel Glioblastoma Treatment   Benzinga
07:00AM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), today announced that the U.S. Food and Drug Administration (FDA) has granted the Company orphan drug designation for its lead investigational drug, Rhenium NanoLiposomes (RNL) for the treatment of patients with recurrent glioblastoma.   GlobeNewswire Inc
Aug 26, 2020
11:57AM EDT  Insider Buys Plus Therapeutics's Shares   Benzinga
Aug 14, 2020
12:23PM EDT  Insider Buys Plus Therapeutics's Stock   Benzinga
Aug 13, 2020
11:07AM EDT  Insider Buys Plus Therapeutics's Shares   Benzinga
Aug 10, 2020
07:44AM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company), today announced financial and business results for its Second Quarter Fiscal Year 2020 ended June 30, 2020.   GlobeNewswire Inc
06:37AM EDT  Plus Therapeutics Q2 EPS $(0.45) Beats $(0.75) Estimate, Sales $185.00K Down From $302.00K YoY   Benzinga
04:10AM EDT  Earnings Scheduled For August 10, 2020   Benzinga
Aug 3, 2020
07:00AM EDT  Plus Therapeutics, Inc. (Nasdaq: PSTV) (the Company) today announced that it will report its Second Quarter Fiscal Year 2020 financial results after the close of market on August 10, 2020. The company plans to hold a conference call and live audio webcast at 5:00 PM Eastern Time to discuss its financial results and provide a general business update.   GlobeNewswire Inc
Jul 28, 2020
07:21AM EDT  Plus Therapeutics Reports Completion Of Fifth Dose Escalation Cohort Of ReSPECT Glioblastoma Trial, Expansion Of Trial Sites   Benzinga
07:00AM EDT  Plus Therapeutics, Inc. (Nasdaq:PSTV) (the Company) today announced the successful completion of the fifth cohort of the ReSPECT Clinical Trial and expansion to a second clinical trial site, the UT Southwestern Medical Center in Dallas.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC